Key result
IVIG prompts full recovery in a patient with enterovirus 71-associated opsoclonus-myoclonus ataxia syndrome.
Why the study?
Does intravenous immunoglobulin improve outcomes in enterovirus 71-associated opsoclonus-myoclonus ataxia syndrome?
Case Report (n=1)
Does intravenous immunoglobulin improve outcomes in enterovirus 71-associated opsoclonus-myoclonus ataxia syndrome?
Enterovirus 71 should be considered as a potential infectious trigger for opsoclonus-myoclonus ataxia syndrome, which may respond well to intravenous immunoglobulin.
May support IVIG consideration in EV71-associated opsoclonus-myoclonus ataxia syndrome; leaves open efficacy pending controlled studies.
Nonparaneoplastic opsoclonus-myoclonus ataxia syndrome is a rare neuroinflammatory condition featured by opsoclonus, myoclonus, ataxia, and cognitive behavioral disturbance. The authors report an observation of enterovirus 71-associated opsoclonus-myoclonus ataxia syndrome evolving toward full recovery on intravenous intravenous immunoglobulin (IG) treatment. Based on this case report, enterovirus 71 should be added to the list of infectious agents likely involved in opsoclonus-myoclonus ataxia syndrome, including the emerging subgroup of opsoclonus-myoclonus ataxia syndrome recovering without aggressive or prolonged immunosuppressive intervention. Further studies are mandatory to define the precise role, incidence, treatment, and outcome of enterovirus 71 and other infectious agents in benign forms of opsoclonus-myoclonus ataxia syndrome.
No takes yet. Share an insight, caveat, or question.
Sahly et al. (2017) conducted a case report in Enterovirus 71-associated opsoclonus-myoclonus ataxia syndrome (n=1). Intravenous immunoglobulin (IG) was evaluated on Full recovery. Intravenous immunoglobulin treatment led to full recovery in a patient with enterovirus 71-associated opsoclonus-myoclonus ataxia syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: